Valuation: Lantheus Holdings, Inc.

Market Cap 6.51B 5.74B 5.43B 4.92B 9.24B 625B 9.32B 64.96B 25.08B 319B 24.44B 23.91B 1,024B P/E 2026 *
21.1x
P/E 2027 * 17.9x
Enterprise Value 6.29B 5.55B 5.24B 4.76B 8.93B 604B 9.01B 62.78B 24.24B 308B 23.62B 23.11B 989B EV / Sales 2026 *
4.2x
EV / Sales 2027 * 3.58x
Free-Float
88.47%
Yield 2026 *
-
Yield 2027 * -
1 day-0.23%
1 week-0.77%
Current month-1.44%
1 month-1.25%
3 months-9.37%
6 months+33.62%
Current year+49.53%
1 week 99.31
Extreme 99.31
100.28
1 month 99.31
Extreme 99.31
101.43
Current year 63.37
Extreme 63.37
111.86
1 year 49.67
Extreme 49.67
111.86
3 years 47.25
Extreme 47.25
126.89
5 years 22.2
Extreme 22.2
126.89
10 years 7.61
Extreme 7.61
126.89
Manager TitleAgeSince
Chief Executive Officer 66 31/12/2025
Director of Finance/CFO 60 20/09/2018
Chief Tech/Sci/R&D Officer 64 31/07/2025
Director TitleAgeSince
Director/Board Member 80 30/04/2012
Chairman 66 29/02/2024
Director/Board Member 61 31/12/2016
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Tax

Chief Financial Officer

-721 0.0011%
17/08/26 Tax

Controller/Auditor

-463 0.0007%
17/08/26 Tax

Chief Technology Officer

-2,536 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-0.23%-0.77%+96.62%+43.12% 6.51B
+0.23%+2.22%+196.07%+491.25% 23.8B
+1.74%+13.83%+668.26%+118.28% 11.53B
-1.19%+8.92%-30.31%-11.06% 10.67B
-0.63%+2.94%+8.08% - 8.97B
-0.08%+1.06%-27.44%-21.96% 5.81B
-0.98%+0.67%+5.88%-7.12% 4.46B
+1.96%-5.39%+56.56%+61.68% 3.7B
-1.52%+3.35%-14.61%-26.50% 2.9B
+1.46%+3.02% - - 1.49B
Average +0.08%+1.04%+106.57%+80.96% 7.98B
Weighted average by Cap. +0.07%+3.14%+163.16%+190.40%

Financials

2026 *2027 *
Net sales 1.5B 1.32B 1.25B 1.13B 2.13B 144B 2.15B 14.96B 5.78B 73.45B 5.63B 5.51B 236B 1.65B 1.46B 1.38B 1.25B 2.35B 159B 2.37B 16.5B 6.37B 81B 6.21B 6.07B 260B
Net income 320M 282M 266M 242M 453M 30.67B 458M 3.19B 1.23B 15.65B 1.2B 1.17B 50.25B 392M 346M 327M 297M 556M 37.65B 562M 3.91B 1.51B 19.22B 1.47B 1.44B 61.69B
Net Debt -219M -193M -182M -165M -310M -20.98B -313M -2.18B -842M -10.71B -821M -803M -34.38B -598M -527M -498M -452M -848M -57.36B -856M -5.96B -2.3B -29.28B -2.24B -2.2B -94B
Logo Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases.
Employees
1,193
Date Price Change Volume
29/09/26 US$99.51 -0.23% 1,233,155
28/09/26 US$99.74 0.00% 1,248,096
25/09/26 US$99.74 +0.02% 952,394
24/09/26 US$99.72 -0.25% 938,569
23/09/26 US$99.97 -0.03% 865,432
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
99.74USD
Average target price
107.74USD
Spread / Average Target
+8.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LNTH Stock